Acute Lymphoid Leukemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for acute lymphoid leukemia. 47 active patents protecting 4 drugs from 2+ originators. First major cliff: 2032. Daily refresh.

4
Approved drugs
47
Active US patents
59/100
Avg vulnerability
—
Annual revenue covered

Originators in Acute Lymphoid Leukemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Schering) 33 patents Nippon Shinyaku Co., Ltd. 14 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating acute lymphoid leukemia. Each bar = one year. Y-axis scaled to peak year (10 patents).

10
27
3
28
2
29
2
30
8
32
7
33
7
34
1
36
3
37
1
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Cytarabine
Cytarabine
 Nippon Shinyaku Co., Ltd. 14 51 — 2027-01-23
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Deltasone
prednisone
 Generic (originally Schering) 4 76 — 2027-08-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8168218 Deltasone method of use 80 2028-01-07
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
12133914 Cortef method of use 75 2043-02-23
11904046 Cortef method of use 75 2043-02-23
7850990 Cytarabine method of use 63 2027-01-23
8101582 Decadron method of use 63 2027-12-19
7795316 Decadron method of use 63 2028-08-03
9717740 Cortef method of use 62 2032-11-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
10799642 Decadron formulation 31 2032-05-11
8409606 Decadron formulation 31 2030-05-14
8450287 Decadron formulation 38 2027-12-19
9271931 Cytarabine formulation 43 2027-01-23
10022502 Decadron method of use 45 2034-06-22
10028965 Decadron method of use 45 2034-05-23
10166184 Cytarabine other 45 2033-04-15
10835492 Cytarabine other 45 2033-04-15

Related